Polivy

Active Ingredient(s): Polatuzumab Vedotin-piiq
FDA Approved: * June 10, 2019
Pharm Company: * GENENTECH

Polatuzumab vedotin (INN;[4] brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer.[5] The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.[6][7] The drug was developed by Genentech and Roche.[not verified in body] History In June 2019, polatuz... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Polivy 30 mg/1.88ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 50242-103

Labeler:

Genentech, Inc.

Polivy 140 mg/7.52ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 50242-105

Labeler:

Genentech, Inc.